Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 9—September 2017
Dispatch

Evaluation of 5 Commercially Available Zika Virus Immunoassays

David SafronetzComments to Author , Angela Sloan, Derek R. Stein, Emelissa Mendoza, Nicole Barairo, Charlene Ranadheera, Leanne Scharikow, Kimberly Holloway, Alyssia Robinson, Maya Traykova-Andonova, Kai Makowski, Kristina Dimitrova, Elizabeth Giles, Joanne Hiebert, Rhonda Mogk, Sharla Beddome, and Michael Drebot
Author affiliations: Public Health Agency of Canada, Winnipeg, Manitoba, Canada

Main Article

Table 1

Results of in-house and commercially available Zika virus immunoassays*

Sample collection dpo In-house Zika virus diagnostic results
 DENV PRNT titer Commercial Zika virus serologic assays results
RT-PCR MAC-ELISA PRNT titer Euroimmun IgM Euroimmun IgG Novatec IgM Abcam IgM InBios IgM
12 ND Pos >40 Neg Pos Pos Pos Pos Pos
9 ND Pos >40 Neg Neg Neg Neg Neg Pos
4 ND Pos >40 Neg Neg Neg Neg Pos Pos
27 ND Pos >40 Neg Pos Pos Pos Pos Pos
39 ND Pos >40 Neg Neg Pos Pos Pos Pos
11 ND Pos >40 Neg Pos Pos Pos Pos Pos
109 ND Pos 1,280 20 Neg Pos Neg Neg Pos
49 ND Pos >40 Neg Neg Pos Pos Pos Pos
Unknown ND Pos >40 Neg Neg Neg Neg Neg Pos
4 ND Pos >40 Neg Pos Neg Pos Pos Pos
7 ND Pos >40 Neg Neg Pos Neg Neg Pos
46 ND Pos >40 Neg Neg Pos Pos Pos Pos
Unknown ND Pos >40 Neg Neg Pos Neg Neg Pos
Unknown ND Pos >40 Neg Neg Pos Eq Pos Pos
118 ND Pos >40 Neg Neg Pos Neg Neg Pos
57 ND Pos >40 Neg Pos Neg Pos Pos Pos
66 ND Pos >40 Neg Neg Pos Neg Eq Pos
43 ND Pos 40 Neg Neg Pos Eq Pos Pos
2 ND Pos >40 Neg Neg Neg Pos Neg Pos
41 ND Pos >40 Neg Pos Pos Neg Neg Pos
5 ND Pos >40 Neg Neg Neg Neg Neg Pos
38 ND Pos >40 Neg Neg Pos Neg Neg PZ
4 ND Pos >80 Neg Pos Neg Neg Pos Pos
6 ND Pos >80 Neg Pos Pos Neg Neg Pos
2 ND Pos >80 Neg Neg Pos Neg Eq Pos
12 ND Pos 40 Neg Pos Neg Pos Pos Pos
Unknown ND Pos >80 Neg Pos Neg Pos Pos Pos
28 ND Pos >80 Neg Pos Pos Neg Neg Pos
75 ND Pos >80 20 Neg Pos Neg Neg Pos
68 ND Pos >40 Neg Neg Pos Neg Neg Pos
9 ND Pos Neg >40 Neg Neg Neg Neg PZ
7 ND Pos Neg >40 Neg Neg Neg Neg PZ
31 ND Pos Neg >40 Neg Neg Neg Neg PZ
6 ND Pos Neg >40 Pos Pos Neg Neg Pos
20 ND Pos Neg >40 Neg Neg Pos Pos PZ
36 ND Pos Neg >80 Neg Neg Neg Neg OF
Unknown ND Pos 320 >5,120 Neg Neg Neg Neg Pos
Unknown ND Pos Neg 40 Neg Neg Pos Neg Neg
3 ND Pos Neg >80 Neg Neg Eq Neg Pos
Unknown ND Pos Neg >640 Neg Neg Neg Neg Pos

*Bold indicates false-positive/false-negative results. Underlining indicates inconclusive results that required further testing. DENV, dengue virus; dpo, days postsymptom onset; Eq, equivalent; MAC-ELISA, IgM-capture ELISA; ND, not done; Neg, negative; OF, other flavivirus; Pos, positive; PRNT, plaque reduction neutralization test; PZ, possible Zika virus; RT-PCR, reverse transcription PCR.

Main Article

Page created: August 17, 2017
Page updated: August 17, 2017
Page reviewed: August 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external